Physician profile
Michael J Connor
NPI 1114924578
$5,054.69
in general payments reported to CMS, 2019-2025
32 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $155 · 2021: $702 · 2022: $936 · 2023: $1,032 · 2024: $942 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,998.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,422.32 | 2020-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $701.64 | 2021-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $560.89 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $375.83 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $296.89 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $282.81 | 2020-2025 | |
| Lilly USA, LLC | $222.37 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $212.28 | 2019 | |
| Genzyme Corporation | $133.66 | 2022-2024 | |
| Braintree Laboratories, INC. | $90.46 | 2021-2024 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $90.03 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $68.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $68.07 | 2024-2025 | Vowst |
| Celltrion USA INC. | $65.19 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $54.36 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $54.09 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $43.32 | 2025 | Iqirvo |
| Amgen INC. | $39.55 | 2021 | |
| Alnylam Pharmaceuticals INC. | $38.42 | 2023-2024 | Givlaari |
| Ardelyx, INC. | $33.21 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $29.02 | 2021-2023 | Watchman Access System |
| Qol Medical, LLC | $28.60 | 2023 | Sucraid |
| Romark Laboratories, Lc | $24.89 | 2020 | |
| Organon LLC | $22.74 | 2022 | |
| Nestle Healthcare Nutrition INC. | $21.72 | 2023 | |
| Ferring Pharmaceuticals INC. | $18.04 | 2019 | |
| Mauna Kea Technologies, INC. | $17.79 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.81 | 2023 | Linzess |
| Merck Sharp & Dohme LLC | $12.62 | 2021 | |
| Medtronic, INC. | $12.35 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.